Patersons recommends Eastland
The lead manager of two Eastland Medical capital raisings last year, Patersons, has updated its research note on the malaria treatment developer.
Patersons has recommended Eastland as a speculative buy with a 29c price target in a research note published on the Eastland website.
The report notes that a Phase 2a clinical trial of Eastlands ArTiMist treatment met primary efficacy parameters.
Perth-based Eastland recently drew criticism for its quiet decision to complete a Phase 2 study before moving on to Phase 3 clinical research.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.394M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| EMS (ASX) Chart |
Day chart unavailable